Comparing GDF9 in Mature Follicles and Clinical Outcomes Across Different PCOS Phenotype

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 May 7

PMID 38711644

Authors

Jingjing Cai

Xiangmin Luo

Zhengyao Wang

Zixuan Chen

Donghong Huang

Hui Cao

Jing Chen

Jinxiang Wu

Affiliations

Soon will be listed here.

Abstract

Background: Polycystic ovary syndrome (PCOS) is main cause of anovulatory infertility in women with gestational age. There are currently four distinct phenotypes associated with individualized endocrinology and metabolism. Growth differentiation factor 9 (GDF9) is a candidate as potential biomarker for the assessment of oocyte competence. The effect on oocyte capacity has not been evaluated and analyzed in PCOS phenotypes.

Objective: We aimed to screen the expression levels of GDF9 in mature follicles of women with controlled ovarian hyperstimulation (COS) with different PCOS phenotypes. To determine the correlation between the expression level of GDF9 and oocyte development ability.

Methods: In Part 1, we conducted a retrospective study comparing the clinical outcomes and endocrine characteristics of patients with PCOS according to different subgroups (depending on the presence or absence of the main features of polycystic ovarian morphology (PCOM), hyperandrogenism (HA), and oligo-anovulation (OA)) and non-PCOS control group. We stratified PCOS as phenotype A (n = 29), phenotype B (n = 18) and phenotype D (n = 24). In Part 2, the expression of GDF9 in follicular fluid (FF) and cumulus cells (CCs) were detected by enzyme-linked immunosorbent assay (ELISA) and immunohistochemistry, respectively.

Results: In Part 1, the baseline clinical, hormonal, and ultrasonographic characteristics of the study population were matched with the presence or absence of the cardinal features of each PCOS phenotypes showed a clear difference. Phenotypes A and D had statistically significant associations with blastocyst formation and clinical pregnancy compared with phenotypes B ( < 0.001). In Part 2, the levels of GDF9 in FF and CCs for phenotype A and B were significantly were higher than those of phenotype D ( = 0.019, = 0.0015, respectively). Multivariate logistic regression analysis showed that GDF9 was an important independent predictor of blastocyst formation (P＜0.001). The blastocyst formation rate of phenotype A was higher than that of phenotype B and D (P＜0.001). Combining the results of the two parts, GDF9 appears to play a powerful role in the development of embryos into blastocysts.

Conclusions: GDF9 expression varies with different PCOS phenotypes. Phenotype A had higher GDF9 levels and blastocyst formation ability.

References

Lan J, Wu Y, Wu Z, Wu Y, Yang R, Liu Y . Ultra-Long GnRH Agonist Protocol During IVF/ICSI Improves Pregnancy Outcomes in Women With Adenomyosis: A Retrospective Cohort Study. Front Endocrinol (Lausanne). 2021; 12:609771. PMC: 8202082. DOI: 10.3389/fendo.2021.609771. View

Dumesic D, Meldrum D, Katz-Jaffe M, Krisher R, Schoolcraft W . Oocyte environment: follicular fluid and cumulus cells are critical for oocyte health. Fertil Steril. 2014; 103(2):303-16. DOI: 10.1016/j.fertnstert.2014.11.015. View

Eralp B, Can Ibanoglu M, Engin-Ustun Y . Evaluation of pregnancy and neonatal outcomes according to the phenotypic types of polycystic ovary syndrome: A prospective study. Int J Gynaecol Obstet. 2023; 163(3):894-903. DOI: 10.1002/ijgo.14882. View

Paulini F, Melo E . The role of oocyte-secreted factors GDF9 and BMP15 in follicular development and oogenesis. Reprod Domest Anim. 2011; 46(2):354-61. DOI: 10.1111/j.1439-0531.2010.01739.x. View

Trombly D, Woodruff T, Mayo K . Roles for transforming growth factor beta superfamily proteins in early folliculogenesis. Semin Reprod Med. 2009; 27(1):14-23. PMC: 2947191. DOI: 10.1055/s-0028-1108006. View

Hussein T, Thompson J, Gilchrist R . Oocyte-secreted factors enhance oocyte developmental competence. Dev Biol. 2006; 296(2):514-21. DOI: 10.1016/j.ydbio.2006.06.026. View

Sugiura K, Su Y, Li Q, Wigglesworth K, Matzuk M, Eppig J . Estrogen promotes the development of mouse cumulus cells in coordination with oocyte-derived GDF9 and BMP15. Mol Endocrinol. 2010; 24(12):2303-14. PMC: 2999473. DOI: 10.1210/me.2010-0260. View

Bailey A, Hawkins L, Missmer S, Correia K, Yanushpolsky E . Effect of body mass index on in vitro fertilization outcomes in women with polycystic ovary syndrome. Am J Obstet Gynecol. 2014; 211(2):163.e1-6. DOI: 10.1016/j.ajog.2014.03.035. View

Canipari R . Oocyte--granulosa cell interactions. Hum Reprod Update. 2000; 6(3):279-89. DOI: 10.1093/humupd/6.3.279. View

10.

Swanton A, Story L, McVeigh E, Child T . IVF outcome in women with PCOS, PCO and normal ovarian morphology. Eur J Obstet Gynecol Reprod Biol. 2009; 149(1):68-71. DOI: 10.1016/j.ejogrb.2009.11.017. View

11.

Dumesic D, Richards J . Ontogeny of the ovary in polycystic ovary syndrome. Fertil Steril. 2013; 100(1):23-38. PMC: 4562327. DOI: 10.1016/j.fertnstert.2013.02.011. View

12.

Nasiri N, Moini A, Eftekhari-Yazdi P, Karimian L, Salman-Yazdi R, Zolfaghari Z . Abdominal obesity can induce both systemic and follicular fluid oxidative stress independent from polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2014; 184:112-6. DOI: 10.1016/j.ejogrb.2014.11.008. View

13.

Uk A, Decanter C, Grysole C, Keller L, Behal H, Silva M . Polycystic ovary syndrome phenotype does not have impact on oocyte morphology. Reprod Biol Endocrinol. 2022; 20(1):7. PMC: 8729101. DOI: 10.1186/s12958-021-00874-2. View

14.

Pogrmic-Majkic K, Samardzija D, Stojkov-Mimic N, Vukosavljevic J, Trninic-Pjevic A, Kopitovic V . Atrazine suppresses FSH-induced steroidogenesis and LH-dependent expression of ovulatory genes through PDE-cAMP signaling pathway in human cumulus granulosa cells. Mol Cell Endocrinol. 2017; 461:79-88. DOI: 10.1016/j.mce.2017.08.015. View

15.

Hu Y, Wang P, Yeh S, Wang R, Xie C, Xu Q . Subfertility and defective folliculogenesis in female mice lacking androgen receptor. Proc Natl Acad Sci U S A. 2004; 101(31):11209-14. PMC: 509185. DOI: 10.1073/pnas.0404372101. View

16.

Ramezanali F, Ashrafi M, Hemat M, Arabipoor A, Jalali S, Moini A . Assisted reproductive outcomes in women with different polycystic ovary syndrome phenotypes: the predictive value of anti-Müllerian hormone. Reprod Biomed Online. 2016; 32(5):503-12. DOI: 10.1016/j.rbmo.2016.01.010. View

17.

Dumesic D, Oberfield S, Stener-Victorin E, Marshall J, Laven J, Legro R . Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome. Endocr Rev. 2015; 36(5):487-525. PMC: 4591526. DOI: 10.1210/er.2015-1018. View

18.

Qiao J, Feng H . Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence. Hum Reprod Update. 2010; 17(1):17-33. PMC: 3001338. DOI: 10.1093/humupd/dmq032. View

19.

Si M, Xu W, Qi X, Jiang H, Zhao Y, Li R . Metabolic Syndrome Rather Than Other Phenotypes in PCOS as a Predictive Indicator for Clinical Outcomes in IVF: Comprehensive Phenotypic Assessment across All PCOS Classifications. J Clin Med. 2023; 12(15). PMC: 10420246. DOI: 10.3390/jcm12155073. View

20.

Si M, Qi X, Zhen X, Yang C, Tian T, Long X . Dose Nomogram of Individualization of the Initial Follicle-Stimulating Hormone Dosage for Patients with Polycystic Ovary Syndrome Undergoing IVF/ICSI with the GnRH-Ant Protocol: A Retrospective Cohort Study. Adv Ther. 2023; 40(9):3971-3985. PMC: 10427540. DOI: 10.1007/s12325-023-02582-2. View